Alteogen lnc., of Daejeon, South Korea, dosed the first patient in a phase I trial testing ALT-P7, a HER2-targeting antibody-drug conjugate developed with the company's Nexmab technology, in 42 patients with advanced or recurrent HER2 positive metastatic breast cancer that is not amenable to the current standard therapy.